Epelsiban

Drug Profile

Epelsiban

Alternative Names: 557296; GSK557296

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Infertility; Premature ejaculation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Infertility(In volunteers) in USA (PO, Tablet)
  • 13 Jun 2016 GlaxoSmithKline terminates phase I trial in Infertility (In volunteers) in USA (IV) (NCT02213029)
  • 06 Jun 2016 GlaxoSmithKline plans a phase II trial in Adenomyosis in USA (NCT02794467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top